Carl-Åke Carlsson – CEO of Xellia Pharmaceuticals
Click HERE to download the PDF version
What was the plan when Xellia first emerged in 2008?
We were the market leader for almost all of our anti-infectives, supplying more than half the world market. Our aim was simply to take the APIs (Active Pharmaceutical Ingredients), develop them into formulations, have them registered and get them onto the market. At the same time, we developed a generic pipeline of new anti-infective injectables. In 2012, 3i decided to sell rather than invest in another five to seven-year period. We were lucky to find Novo Holdings A/S, which now owns us through the same investment vehicle that owns Novo Nordisk, Novozymes and holds more than 80 active investments in the life science industry.
What was their plan when they acquired you?
Novo Holdings A/S bought the company to develop it. Most Big Pharma companies have left the anti-infective space and there is an unmet medical need. It can be a financially challenging space, because it is hard to get paid for developing new anti-infe ...